Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel)
What is the background of this study?
Orva-cel is a B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T cell therapy being evaluated in the phase I/II EVOLVE study (NCT03430011) in pateints with relapsed refractory multiple myeloma who had at least three prior lines of therapy.
In this video:
Dr. Luciano Costa (University of Alabama at Birmingham, Birmingham, AL, USA) explains that this study explores the role prophylaxis with Anakinra, an IL-1 signaling inhibitor, on reducing the incidence of grade (G) ≥2 Cytokine Release Syndrome (CRS) after orva-cel treatment at the recommended dose.
Conclusions:
In this nonrandomized evaluation of with orva-cel treatment, the incidence of G ≥2 CRS was lower Anakinra prophylaxis (AKR ppx) in patients receiving AKR ppx. The use of AKR ppx produced no adverse effect on the incidence of neurological events, infection, or macrophage activation syndrome/hemophagocytic lymphohistiocytosis, nor on orva-cel expansion or disease response. These results warrant further study of AKR ppx in CAR T-cell therapy.
Clinical trial information: NCT03430011.
_______________
Improving Lives Through Research and Patient Care
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: @myeloma | [ Ссылка ]
Twitter: @IMFMyeloma | [ Ссылка ]
Instagram: @imfmyeloma | [ Ссылка ]
LinkedIn: [ Ссылка ]
Support the IMF! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
